-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), Johnson & Johnson's Janssen Company's Class 1 biologic new drug teclistamab injection has been approved for clinical use, targeting multiple myeloma (MM)
According to the latest summary data disclosed at the ASCO Annual Meeting in 2021, as of February 4, 2021, 156 patients had received teclistamab treatment, of which 84 were intravenous (IV) and 72 were subcutaneous (SC)